Seres Therapeutics, Inc. Operating Lease Right-of-Use Assets
Seres Therapeutics, Inc. (MCRB) had Operating Lease Right-of-Use Assets of $51.17 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $51.17M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $70.23M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $72.48M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $74.67M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $51.17M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $70.23M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $72.48M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $74.67M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $76.79M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $78.86M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $80.90M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $82.91M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $103.28M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $105.67M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $90.42M 10-K · filed 2025-03-13 | $109.79M 10-K · filed 2024-03-05 |
| 2023-09-30 | $108.11M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $110.28M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $108.91M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $110.98M 8-K · filed 2024-08-15 | |
| 2022-09-30 | $23.75M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $25.00M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $26.25M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $18.21M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $11.59M 10-Q · filed 2021-11-10 | |
| 2021-09-01 | $56.06M 10-K · filed 2023-03-07 | |
| 2021-08-01 | $2.66M 10-Q · filed 2022-11-02 | |
| 2021-07-01 | $5.90M 10-K · filed 2023-03-07 | |
| 2021-06-30 | $12.41M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $8.39M 10-Q · filed 2021-05-04 | |
| 2021-01-07 | $5.90M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $9.04M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $9.66M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $10.26M 10-Q · filed 2020-07-28 | |
| 2020-03-31 | $10.82M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $11.36M 10-K · filed 2021-03-02 | |
| 2019-09-30 | $11.90M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $12.64M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $13.20M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |